SCHEMBL2336029

SCHEMBL2336029

CCOC(=O)c1cc(C)nn1Cc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
NPSR1 Q6W5P4 3/20 0.59
SMN1; SMN2 Q16637 5/20 0.58
POLB P06746 2/20 0.58
TDP1 Q9NUW8 2/20 0.55
KDM4E B2RXH2 2/20 0.53
MAPK1 P28482 1/20 0.53
RAB9A P51151 4/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 4/20 0.48
NPC1 O15118 2/20 0.48
CYP19A1 P11511 1/20 0.48
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7829135 0.90 SMN1; SMN2 (0.66) MAPTNPSR1SMN1; SMN2POLBTDP1
SCHEMBL4006702 0.88 SMN1; SMN2 (0.74) MAPTSMN1; SMN2POLBTDP1KDM4E
SCHEMBL30028627 0.87 MAPT (0.68) MAPTNPSR1SMN1; SMN2POLBTDP1
SCHEMBL7234307 0.85 MAPT (0.56) MAPTNPSR1SMN1; SMN2POLBTDP1
SCHEMBL6258641 0.83 MAPT (0.64) MAPTNPSR1POLBRAB9AGAA
SCHEMBL8511661 0.80 KMT2A (0.60) MAPTSMN1; SMN2POLBKDM4EMAPK1
SCHEMBL6188814 0.79 MAPT (0.52) MAPTNPSR1SMN1; SMN2POLBTDP1
SCHEMBL6348254 0.77 ENPP3 (0.62) MAPTSMN1; SMN2TDP1KDM4EMAPK1
SCHEMBL7231587 0.77 SMN1; SMN2 (0.54) MAPTSMN1; SMN2POLBTDP1MAPK1
SCHEMBL18718147 0.77 SMN1; SMN2 (0.47) MAPTSMN1; SMN2POLBTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534155-B1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENT MANAGEMENT PTY LTD (AU) 2018-04-11 EP disclosed
US-9540387-B2 Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2017-01-10 US disclosed
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections BIOTA SCIENT MANAGEMENT (AU) 2016-02-18 US disclosed
US-9163029-B2 Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2015-10-20 US disclosed
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-8604034-B2 Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-12-10 US disclosed
EP-2534155-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS Biota Scientific Management Pty Ltd (AU) 2012-12-19 EP disclosed
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2011-08-25 US disclosed
WO-2011094823-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2011-08-11 WO disclosed
EP-1066257-A2 HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE Sugen, Inc. (US) 2001-01-10 EP disclosed
WO-1999048868-A9 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN INC (US) 2000-04-20 WO disclosed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MAPT 4436/4885NPSR1 1458/4885SMN1; SMN2 497/4885
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections FURIN, SQOR, SUCNR1 MAPT 4436/4885NPSR1 1458/4885SMN1; SMN2 497/4885
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MAPT 4436/4885NPSR1 1458/4885SMN1; SMN2 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.